Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK-001 in geographic atrophy secondary to AMD
NCT03845582Phase 3Completed
- Sponsor
- Alkeus Pharmaceuticals, Inc.
- Start
- May 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in geographic atrophy (GA) comparing ALK-001 with Placebo (2 arms). Primary endpoint: Growth Rate of Geographic Atrophy Lesions as Assessed by Fundus Autofluorescence at 24 months. Started May 2019; status: completed.
02
Drugs
gildeuretinol
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT03845582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845582.